ATA-100 / Atamyo Therap - LARVOL DELTA

Gene therapy for LGMDR9: preliminary results of a dose‐escalation study (ESGCT 2023) - P1/2 | "Patients with neutralizing anti-AAV9 antibodies are excluded. Status of the study, including preliminary clinical data and muscle biopsy results will be presented."

Gene therapy • Cardiovascular • Congestive Heart Failure • Gene Therapies • Heart Failure • Muscular Dystrophy • FKRP

Advanced tetra amino (ATA-100) cobalt(II) phthalocyanine-based metallo-covalent organic polymer for sensitively detecting volatile organic compounds. (PubMed, Turk J Chem) - "ATA-100 showed the highest sensitivity for ethyl butyrate. The results have confirmed the possibility of utilizing ATA-100 COP-based surface acoustic wave (SAW) sensors for a wide variety of applications, including indoor air quality and environmental monitoring of volatile organic compounds (VOCs)."

Journal • Metastases

GNT0006 Gene Therapy Trial in Patients With LGMDR9 (clinicaltrials.gov) - P1/2 | N=39 | Recruiting | Sponsor: Atamyo Therapeutics | Not yet recruiting ➔ Recruiting | Initiation date: May 2022 ➔ Aug 2022

Enrollment open • Trial initiation date • Gene Therapies • Muscular Dystrophy